Clinical trials: Heart Transplantation, active
Microsporidiosis Intestinal, Heart Transplant Infection
Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)
The investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on microsporidiosis among heart transplant patients.
- Trial name
- CARMIC (NCT06986980)
- Where
- France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Clermont-Ferrand
Transplant
OCS Heart Perfusion Post-Approval Registry
The objective of this post-approval registry is to provide additional real-world evidence of the performance of the OCS Heart System to preserve DBD and DCD donor hearts.
- Trial name
- NCT05047068
- Testing
- OCS Heart System
- Where
- 27 sites in United States
- Volunteers
- 350 people
- Sponsor
- TransMedics
Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure
Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial
This is a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in elderly patients with heart failure with preserved ejection…
- Trial name
- NCT07628777
- Testing
- Fecal Microbiota Transplantation (FMT) Capsules
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Chronic Heart Failure
Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure
The purpose of this study is to determine whether people with CHF, who often have different gut bacteria from healthy, would benefit from replacing their gut bacteria with healthy donor bacteria (also known as Intestinal…
- Trial name
- IMT (NCT07490054)
- Testing
- MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Melana Yuzefpolskaya, MD
Stem Cell Transplant Complications, Acute Graft Versus Host Disease
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region.
- Conditions
- Stem Cell Transplant Complications, Acute Graft Versus Host Disease, Acute Kidney Injury, Major Adverse Cardiac Events
- Trial name
- NCT06386445
- Testing
- Serum metabolomics sequencing
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Cardiac Allograft Vasculopathy
Early Post Transplant Cardiac Allograft Vasculopathy
Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal…
- Trial name
- ECAV (NCT03217786)
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Failure
XVIVO Heart Transplant Study in Clinical Practice
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.
- Trial name
- HOPE for All (NCT07556588)
- Testing
- XVIVO Heart Assist Transport System
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- XVIVO Perfusion
Cirrhosis, Registered on Transplant List
Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.
The aim of this multicenter prospective interventional pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT).
- Trial name
- CARDIOFIBROCIR (NCT06327308)
- Testing
- MRI, Blood sampling
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Heart Transplant Rejection
Molecular Evidence of Rejection Intervention Trial
MERIT is a double-blind, multi-center, placebo-controlled, randomized clinical trial. Heart transplant recipients with dual-positive GEP/dd-cfDNA assays with a corresponding negative biopsy between 2 months and 2 years…
- Trial name
- MERIT (NCT07905599)
- Testing
- Prednisone
- Volunteers
- 200 people
- Sponsor
- CareDx
Congestive Heart Failure
Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease
Hypothesis: Tissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of…
- Trial name
- NCT01099982
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Utah
Heart Transplant
OCS Heart EXPAND + CAP Continued Follow-Up
Post-approval observational study of subjects that were enrolled and transplanted in the OCS Heart EXPAND and OCS Heart EXPAND CAP studies.
- Trial name
- NCT05096299
- Testing
- OCS Heart
- Volunteers
- 150 people
- Sponsor
- TransMedics
Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications…
- Trial name
- REFIL-2 (NCT07695363)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy
- Where
- 4 sites in Canada
- Volunteers
- 866 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Anxiety, Heart Transplant Patients
Using Breathing Techniques to Ease Anxiety in ICU Patients Awaiting Heart Transplants
The goal of this clinical trial is to learn whether a breathing-based relaxation technique called heart rate variability biofeedback (HRVB) can help reduce anxiety in adult patients who are in the intensive care unit (ICU) and…
- Trial name
- NCT07381023
- Testing
- Heart Rate Variability Biofeedback (HRVB)
- Volunteers
- 60 people
- Sponsor
- Hartford HealthCare
Cardiac Transplant Rejection
A Study of AI in Cardiac Transplant in Echocardiographic Analysis (ORACLE)
The purpose of this research is to detect episodes of rejection versus non-rejection after cardiac transplant and the diagnostic accuracy of an Artificial Intelligence (AI) algorithm using the data from an ECG (electrocardiogram)…
- Trial name
- ORACLE (NCT06178744)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic
Kidney Disease, Chronic, Renal Transplant Failure
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
Rationale: Sodium glucose co transporter 2 (SGLT2) inhibitors are a relatively new class of agents, originally developed as oral antihyperglycemic drugs.
- Conditions
- Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure
- Trial name
- NCT05374291
- Testing
- Dapagliflozin 10 mg/day (oral)
- Where
- 101 sites in Australia, Belgium and 4 more
- Volunteers
- 1,750 people
- Sponsor
- University Medical Center Groningen
Heart Transplantation
First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System
The main objective of PEGASE is to validate the recovery of a satisfactory cardiac function of a transplanted heart after a prolonged period of preservation by an ex-vivo perfusion device.
- Trial name
- PEGASE (NCT06035991)
- Testing
- Heart transplantation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Transplant Failure, Heart Transplant Rejection
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography…
- Conditions
- Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection
- Trial name
- LEONE-HT (NCT05184426)
- Testing
- Echocardiogram, Cardiac magnetic resonance, Coronary angiography
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Juan Francisco Delgado Jimenez
Tricuspid Regurgitation, Heart Failure NYHA Class III
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
The use of implantable left ventricular assist devices (LVAD) has increased over the last decade; partly because the newer continuous flow pumps feature a smaller design and better durability.
- Conditions
- Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT02537769
- Testing
- Left ventricular assist device (LVAD), Tricuspid Valve Repair (TVR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Heart Transplant Failure, Kidney Failure
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Kidney failure is common in heart transplant recipients and is a major cause of morbidity and mortality. Sodium-glucose transporter 2 (SGLT2) inhibitors were developed as antidiabetics but were subsequently shown to reduce the…
- Trial name
- DAPARHT (NCT05321706)
- Testing
- Dapagliflozin 10 mg
- Where
- 6 sites in Netherlands, Norway and 1 more
- Volunteers
- 430 people
- Sponsor
- Oslo University Hospital